Brief Your CEO: It May Become Easier to Get CMS Stark Clearance for Business Deals with Referral Sources
Part of the challenge of running a lab compliance program is making your officers aware of how business transactions your lab makes with a physician that refers patients to you for testing creates the risk of liability under the Stark Law. That’s why it’s crucial to go to great pains to structure your deals so […]
Part of the challenge of running a lab compliance program is making your officers aware of how business transactions your lab makes with a physician that refers patients to you for testing creates the risk of liability under the Stark Law. That’s why it’s crucial to go to great pains to structure your deals so they don’t cross the Stark Law lines. Unfortunately, you can never be totally sure if your arrangement complies. One of the best ways to allay your concerns is by asking the OIG for an advisory opinion. If the OIG blesses the arrangement, you can feel good about proceeding; if not, you can take the proposed deal off the table or restructure it to address the OIG’s Stark Law concerns. At least that’s how it’s supposed to work. But in the real world, getting Stark Law advisory opinions is tricky and thus not resorted to as often as you’d expect. The good news that you should convey to your C-Suite is that getting an advisory opinion may be back in play soon. In late July, CMS proposed to update the advisory opinion process to make it easier for labs and other providers to get an OIG determination about whether a proposed business arrangement would violate the Stark Law. Here are the key things you need to know to brief your CEO and officers on the situation. The Current Process The first thing the officers need to understand is how the current CMS Stark Law advisory opinion process works. The process is modeled on the one the OIG uses to issue advisory opinions under Stark’s sister law, the Anti-Kickback Statute (AKS). That’s not surprising. After all, both laws are designed to prevent conflict of interest and payment for referrals. But there are also important differences between the laws that makes the AKS advisory opinion model unsuitable for Stark. For one thing, Stark Law advisory opinions are more badly needed. Explanation: AKS is a criminal statute while the Stark Law is a strict liability civil payment statute. And unlike the AKS, qualifying for an exception is mandatory to avoid liability under Stark. That makes the need for Stark guidance through the advisory opinion process more important than it is for the AKS. But in spite of this, CMS has issued only 30 advisory opinions since the advisory opinion regulations were adopted in 1998. Another big difference is that unlike the case with AKS, only the requestor, i.e., the provider that asks for the advisory opinion, is allowed to rely on a Stark Law advisory opinion. In other words, the opinion doesn’t apply to the other non-requesting parties to the arrangement nor third parties seeking to use the advisory opinion as guidance for their own transactions. That substantially limits the value of an advisory opinion. The 5 Proposed Changes The fact that the Stark Law process is troubled has been obvious to providers for decades. But CMS didn’t get the memo. For CMS, the need to fix the Stark Law advisory opinion process came to light in July 2018 when the agency issued a Request for Information (RFI) on adapting Stark to value-based care. See Lab Industry Report (LIR), July 16, 2018. The advisory opinion process was the subject of many of the comments, even though it wasn’t one of the issues listed in the RFI. The good news is that CMS got the message and decided to tinker with the process. The July 2019 proposal suggests five changes to the Stark Law advisory opinion process that you should go over with your officers. 1 Broaden Scope of Issues Advisory Opinion Can Cover Current Process: CMS will not provide a Stark Law opinion if:
- The request is not related to a named individual or entity;
- CMS is aware that the same or substantially the same course of action is under investigation or is or has been the subject of a proceeding involving HHS or another governmental agency; or
- The agency believes that it can’t make an informed opinion or could only make an informed opinion after extensive investigation, clinical study, testing or collateral inquiry.
- Remove limits on the universe of individuals and entities that can rely on an advisory opinion;
- Add language listing the permissible uses of an advisory opinion;
- Limit its right to rescind an advisory opinion to only when: (1) there’s a material regulatory change that impacts the conclusions reached; or (2) a party that receives a negative advisory opinion asks the agency reconsider in light of legal or factual developments;
- Issue advisory opinions based on hypotheticals or general questions of interpretation;
- Establish an expedited process for obtaining advisory opinions; and
- Cap fees for advisory opinions and/or eliminate the initial fee.
This content is exclusive to Lab Compliance Advisor subscribers
Start a Free Trial for immediate access to this article and our entire archive of over 20 years of LCA reports.